$1.35
2.88% yesterday
Nasdaq, Nov 06, 10:16 pm CET
ISIN
US74065P1012
Symbol
PRLD

Prelude Therapeutics Inc Stock price

$1.35
-0.11 7.53% 1M
+0.55 69.60% 6M
+0.08 5.88% YTD
+0.03 2.27% 1Y
-6.33 82.42% 3Y
-42.52 96.92% 5Y
-17.65 92.89% 10Y
-17.65 92.89% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
-0.04 2.88%
ISIN
US74065P1012
Symbol
PRLD
Industry

Key metrics

Basic
Market capitalization
$76.4m
Enterprise Value
$3.2m
Net debt
positive
Cash
$73.2m
Shares outstanding
56.6m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.0
Financial Health
Equity Ratio
74.9%
Return on Equity
-96.7%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-171.0m
EBIT
- | $-132.9m
Net Income
- | $-79.7m
Free Cash Flow
$-108.5m
Growth (TTM | estimate)
Revenue
- | -100.0%
EBITDA
- | -23.9%
EBIT
- | 4.9%
Net Income
- | 37.3%
Free Cash Flow
-1.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.9
Short interest
6.9%
Employees
131
Rev per Employee
$50.0k
Show more

Is Prelude Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Prelude Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Prelude Therapeutics Inc forecast:

8x Buy
80%
1x Hold
10%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a Prelude Therapeutics Inc forecast:

Buy
80%
Hold
10%
Sell
10%

Financial data from Prelude Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7 7
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
1% 1%
410%
- Research and Development Expense 118 118
14% 14%
1,686%
-138 -138
5% 5%
-1,971%
- Depreciation and Amortization 1.77 1.77
51% 51%
25%
EBIT (Operating Income) EBIT -140 -140
6% 6%
-1,996%
Net Profit -127 -127
4% 4%
-1,817%

In millions USD.

Don't miss a Thing! We will send you all news about Prelude Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prelude Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected...
Neutral
GlobeNewsWire
3 days ago
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to ...
Neutral
GlobeNewsWire
4 days ago
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of two abstracts with preclinical data on the Company's JAK2V617F mutant selective inhibitors and CALR-targeted degrader antibody conjugates (DACs) discovery program, both accepted for oral...
More Prelude Therapeutics Inc News

Company Profile

Prelude Therapeutics, Inc. operates as a cancer drug discovery company. It focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Gopi Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.

Head office United States
CEO Krishna Vaddi
Employees 131
Founded 2016
Website preludetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today